At six months following the initiation of vericiguat, the prescription rates of the following heart failure medications were not significantly different between the patients with ≥2 hospitalizations and those with <2 hospitalizations: renin–angiotensin system inhibitors (12/12 versus 23/23, p = 1.0), beta-blockers (12/12 versus 22/23, p = 0.46), mineralocorticoid receptor antagonist (12/12 versus 21/23, p = 0.29), and sodium–glucose co-transporter 2 inhibitor (11/12 versus 21/23, p = 0.97). The gene discussed is REN; the disease is heart failure.